NCCN Guidelines Insights: Breast Cancer, Version 3.2018.


Journal

Journal of the National Comprehensive Cancer Network : JNCCN
ISSN: 1540-1413
Titre abrégé: J Natl Compr Canc Netw
Pays: United States
ID NLM: 101162515

Informations de publication

Date de publication:
02 2019
Historique:
entrez: 22 2 2019
pubmed: 23 2 2019
medline: 22 7 2020
Statut: ppublish

Résumé

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

Identifiants

pubmed: 30787125
pii: insbr1702
doi: 10.6004/jnccn.2019.0009
doi:
pii:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

118-126

Informations de copyright

Copyright © 2019 by the National Comprehensive Cancer Network.

Auteurs

Matthew P Goetz (MP)

1Mayo Clinic Cancer Center.

William J Gradishar (WJ)

2Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Benjamin O Anderson (BO)

3University of Washington/Seattle Cancer Care Alliance.

Jame Abraham (J)

4Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.

Rebecca Aft (R)

5Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

Kimberly H Allison (KH)

6Stanford Cancer Institute.

Sarah L Blair (SL)

7UC San Diego Moores Cancer Center.

Harold J Burstein (HJ)

8Dana-Farber/Brigham and Women's Cancer Center.

Chau Dang (C)

9Memorial Sloan Kettering Cancer Center.

Anthony D Elias (AD)

10University of Colorado Cancer Center.

William B Farrar (WB)

11The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

Sharon H Giordano (SH)

12The University of Texas MD Anderson Cancer Center.

Lori J Goldstein (LJ)

13Fox Chase Cancer Center.

Steven J Isakoff (SJ)

14Massachusetts General Hospital Cancer Center.

Janice Lyons (J)

4Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.

P Kelly Marcom (PK)

15Duke Cancer Institute.

Ingrid A Mayer (IA)

16Vanderbilt-Ingram Cancer Center.

Meena S Moran (MS)

17Yale Cancer Center/Smilow Cancer Hospital.

Joanne Mortimer (J)

18City of Hope National Medical Center.

Ruth M O'Regan (RM)

19University of Wisconsin Carbone Cancer Center.

Sameer A Patel (SA)

13Fox Chase Cancer Center.

Lori J Pierce (LJ)

20University of Michigan Rogel Cancer Center.

Elizabeth C Reed (EC)

21Fred & Pamela Buffett Cancer Center.

Hope S Rugo (HS)

22UCSF Helen Diller Family Comprehensive Cancer Center.

Amy Sitapati (A)

7UC San Diego Moores Cancer Center.

Karen Lisa Smith (KL)

23The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Mary Lou Smith (ML)

24Research Advocacy Network.

Hatem Soliman (H)

25Moffitt Cancer Center.

Melinda L Telli (ML)

6Stanford Cancer Institute.

John H Ward (JH)

26Huntsman Cancer Institute at the University of Utah.

Jessica S Young (JS)

27Roswell Park Comprehensive Cancer Center; and.

Dorothy A Shead (DA)

28National Comprehensive Cancer Network.

Rashmi Kumar (R)

28National Comprehensive Cancer Network.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH